📊 CMPX Key Takeaways
Is Compass Therapeutics, Inc. (CMPX) a Good Investment?
Compass Therapeutics is a pre-revenue biotech company with negative profitability and substantial cash burn ($17.3M operating; $17.4M free cash flow annually). While the balance sheet is strong with $55.2M cash and zero debt, the lack of revenue generation and persistent operating losses (-$20.3M) indicate the company has not achieved commercial viability. At current burn rates, cash runway extends approximately 3+ years, but the path to profitability remains uncertain without demonstrated revenue.
Compass Therapeutics has a clean balance sheet with no long-term debt and very strong near-term liquidity, but the core fundamental picture remains weak because the business is still generating no revenue and substantial operating losses. Losses improved year over year, which is a positive, yet cash burn remains high relative to cash on hand, making future financing risk and execution on clinical/commercial milestones central to the outlook.
Compass Therapeutics, Inc. Key Strengths (CMPX)
- Strong balance sheet with $186.5M stockholders' equity and minimal liabilities ($18.7M)
- Substantial cash position of $55.2M with no long-term debt, providing financial flexibility
- Excellent liquidity ratios (current ratio 19.04x) enabling operational flexibility during development phase
- Debt-free capital structure with $196.79M of equity and no long-term debt
- Very strong current and quick ratios at 15.02x, indicating low near-term balance sheet stress
- Net loss improved 34.7% year over year, showing some cost-loss narrowing
CMPX Stock Risks: Compass Therapeutics, Inc. Investment Risks
- Zero revenue with complete loss of prior-year revenue (-100% YoY), indicating failed or absent commercialization
- Significant operating cash burn of $17.3M annually against limited revenue generation capacity
- High execution risk inherent in biotech sector; company remains pre-commercial with unproven pipeline value
- Revenue fell to $0.00, leaving the company fully dependent on external capital or balance sheet resources
- Operating cash outflow of $49.14M versus $30.64M of cash implies limited cash runway if burn is not reduced
- Negative ROE of -33.8% and ROA of -30.3% reflect weak capital efficiency and ongoing unprofitability
Key Metrics to Watch
- Quarterly revenue generation and time to first commercial milestone
- Operating cash burn rate and remaining cash runway
- Progress on clinical trials and regulatory approvals for pipeline candidates
- Quarterly operating cash burn versus cash and equivalents
- Any sustained revenue generation or major improvement in operating loss
Compass Therapeutics, Inc. (CMPX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.04x current ratio provides a solid financial cushion.
CMPX Profit Margin, ROE & Profitability Analysis
CMPX vs Healthcare Sector: How Compass Therapeutics, Inc. Compares
How Compass Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Compass Therapeutics, Inc. Stock Overvalued? CMPX Valuation Analysis 2026
Based on fundamental analysis, Compass Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Compass Therapeutics, Inc. Balance Sheet: CMPX Debt, Cash & Liquidity
CMPX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Compass Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.36 indicates the company is currently unprofitable.
CMPX Revenue Growth, EPS Growth & YoY Performance
CMPX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$10.5M | $-0.08 |
| Q2 2025 | N/A | -$10.8M | $-0.10 |
| Q3 2024 | N/A | -$7.8M | $-0.08 |
| Q2 2024 | N/A | -$7.8M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Compass Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CMPX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Compass Therapeutics, Inc. (CIK: 0001738021)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CMPX
What is the AI rating for CMPX?
Compass Therapeutics, Inc. (CMPX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CMPX's key strengths?
Claude: Strong balance sheet with $186.5M stockholders' equity and minimal liabilities ($18.7M). Substantial cash position of $55.2M with no long-term debt, providing financial flexibility. ChatGPT: Debt-free capital structure with $196.79M of equity and no long-term debt. Very strong current and quick ratios at 15.02x, indicating low near-term balance sheet stress.
What are the risks of investing in CMPX?
Claude: Zero revenue with complete loss of prior-year revenue (-100% YoY), indicating failed or absent commercialization. Significant operating cash burn of $17.3M annually against limited revenue generation capacity. ChatGPT: Revenue fell to $0.00, leaving the company fully dependent on external capital or balance sheet resources. Operating cash outflow of $49.14M versus $30.64M of cash implies limited cash runway if burn is not reduced.
What is CMPX's revenue and growth?
Compass Therapeutics, Inc. reported revenue of $0.0.
Does CMPX pay dividends?
Compass Therapeutics, Inc. does not currently pay dividends.
Where can I find CMPX SEC filings?
Official SEC filings for Compass Therapeutics, Inc. (CIK: 0001738021) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CMPX's EPS?
Compass Therapeutics, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CMPX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Compass Therapeutics, Inc. has a C grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CMPX stock overvalued or undervalued?
Valuation metrics for CMPX: ROE of -9.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CMPX's AI grade for 2026?
Our dual AI analysis gives Compass Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CMPX's free cash flow?
Compass Therapeutics, Inc.'s operating cash flow is $-17.3M, with capital expenditures of $82.0K.
How does CMPX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.8% (avg: 15%), current ratio 19.04 (avg: 2).